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Abstract: A linked population-based database is being created in Denmark for research 
on drug safety during pregnancy. It combines information from the Danish National Health 
Service Prescription Database (with information on all prescriptions reimbursed in Denmark 
since 2004), the Danish Fetal Medicine Database, the Danish National Registry of Patients, 
and the Medical Birth Registry. The new linked database will provide validated information on 
malformations diagnosed both prenatally and postnatally. The cohort from 2008 to 2014 will 
comprise 589,000 pregnancies with information on 424,000 pregnancies resulting in live-born 
children, ∼420,000 pregnancies undergoing prenatal ultrasound scans, 65,000 miscarriages, 
and 92,000 terminations. It will be updated yearly with information on ∼80,000 pregnancies. 
The cohort will enable identification of drug exposures associated with severe malformations, 
not only based on malformations diagnosed after birth but also including those having led to 
termination of pregnancy or miscarriage. Such combined data will provide a unique source of 
information for research on the safety of medications used during pregnancy.
Keywords: malformations, teratology, therapeutic drug monitoring, epidemiological methods, 
registries
Introduction
In all, .50% of pregnant women redeem at least one prescription during pregnancy,1,2 
but the fetal effects of many types of medications have not been ascertained.3 This 
paucity of information hampers management of a number of diseases during pregnancy 
as well as the development of new obstetric medications.4
In the early 1960s, Lenz et al5 and McBride6 first described an association between 
the use of medication (thalidomide) during pregnancy and severe malformations. Since 
then, a number of teratological medications have been described.7 Unfortunately, suf-
ficient information on safety during pregnancy is still lacking for many medications, 
in part due to methodological limitations. No existing in vitro or animal models can 
provide valid information on the likelihood of fetal risk. Randomized controlled 
trials focused on adverse fetal effects are almost always unethical. For randomized 
controlled trials that would be possible to conduct during pregnancy (eg, studies on 
discontinuation of antidepressants), huge sample sizes are needed to investigate specific 
malformations. Studies relying on spontaneous reports of malformations are subject to 
severe bias, including recall bias, and the interpretation of the findings is hampered by 
the fact that spontaneous report system data do not inherently include the underlying 
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denominator. Consequently, most information on the use of 
medications during pregnancy derives from epidemiological 
studies, whose quality relies heavily on the validity of the 
underlying data.
Studies on the safety of medications used during preg-
nancy that are based on existing epidemiological data sources 
have a number of limitations.8–10 First, results can be distorted 
by missing data on prenatally diagnosed malformations that 
led to miscarriage or pregnancy termination. The resulting 
bias would be proportional to the severity of the malforma-
tions.11 For example, phocomelia (as seen after thalidomide 
exposure), now often detected during prenatal screening, is 
associated with a high propensity for pregnancy termina-
tion.12 Thus, this malformation would be potentially unde-
tectable using the sole data on live-born children. Second, 
exposure information is subject to some extent of misclas-
sification regardless of whether it is based on self-report or 
administrative databases. Third, the validity of malformation 
diagnoses may vary according to the type and severity of the 
defect or sequence. Finally, no known teratogens increase the 
risk of all birth defects, and therefore, specific drugs need to 
be studied in relation to specific birth defects, requiring very 
large datasets. The consequences of these limitations include 
potentially delayed or failed detection of teratological drug 
effects or reporting of false-positive associations (eg, related 
to confounding by indication).
Here, we describe the creation of a large nationwide data-
base, containing information on malformations diagnosed 
both prenatally and postnatally and linked to information on 
prescriptions redeemed during pregnancy.
Data linkage
Data will be linked using the unique ten-digit civil personal 
register (CPR) number, assigned by the Danish Civil Regis-
tration to all Danish citizens at birth or upon immigration.13 
The cohort will comprise all clinically recognized pregnan-
cies in Denmark starting in 2008 by linking the Danish 
National Registry of Patients (covering all Danish hospitals), 
the Danish Fetal Medicine Database, and the Danish Medical 
Birth Registry.14 Information on exposure to medications will 
be obtained through linkage with the Danish National Health 
Service Prescription Database (DNHSPD).15
The cohort from 2008 to 2014 will comprise 589,000 
pregnancies with information on 424,000 pregnancies result-
ing in live-born children, ∼420,000 undergoing prenatal 
ultrasound scans, 92,000 terminations, 65,000 miscarriages, 
2,000 stillborn children, and 6,000 with other outcomes 
(including ectopic pregnancies). Data will be updated yearly 
with information on ∼80,000 pregnancies.
Danish National Registry of Patients
The registry contains information on all in- and outpatient 
contacts in the hospital system since 1995.16 Diagnoses 
are coded according to the tenth revision of the Interna-
tional Classification of Diseases. The database includes 
information on spontaneous and induced abortions and 
on malformations diagnosed postnatally (ie, also years 
after birth).
Danish Fetal Medicine Database
This nationwide clinical quality database was established 
both to enable quality assessment of the prenatal screening 
in Denmark and to provide data for research.17 Importantly, it 
holds information on malformations diagnosed prenatally. All 
departments involved in prenatal screening (such as nuchal 
translucency and malformation scans) provide data to this 
central database. The data are collected in a standardized way 
as all departments use the same software (Astraia, Munich, 
Germany) to store the data as part of everyday clinical man-
agement. The departments also use identical algorithms to 
collect and send the data to the central database, hosted by 
the Danish Regions’ Quality Assessment Unit,18 where they 
are linked to information from the Medical Birth Registry, 
the Danish National Registry of Patients, and the Danish 
Central Cytogenetic Registry using the CPR numbers of the 
mother and her offspring.
The population in the Fetal Medicine Database consists of 
women accepting prenatal screening or ultrasound. Data on 
all first trimester screenings and second trimester malforma-
tion scans are included. Between 2008 and 2012, ∼92% of 
the pregnant population in Denmark underwent first trimes-
ter screening (eg, 279,105 pregnancies between 2008 and 
201217), and ∼96% of the pregnancies were scanned between 
18 weeks and 22 weeks of gestation. In all, ,1% of the preg-
nancies that reach 12 weeks of gestation undergo no prenatal 
screening. The local databases contain information such as 
crown-rump length, nuchal translucency thickness, method 
of conception, maternal characteristics (including ethnicity, 
weight, and smoking status), results of prenatal invasive 
testing (cytogenetic results), and prenatally diagnosed mal-
formations. Importantly, information on pregnancies without 
prenatal screening is available through the linked Medical 
Birth Registry. Table 1 provides an overview of central vari-
ables in the Danish Fetal Medicine Database.
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Danish Medical Birth Registry
The Danish Medical Birth Registry holds information on 
births in Denmark since 1973.14 It includes information on 
all stillborn and live-born children, including gestational age 
at birth and birth weight.
Danish National Health Service 
Prescription Database
The health care system in Denmark provides tax-financed 
partial reimbursement for most prescription medications. 
The entire country is served by pharmacies equipped with 
electronic accounting systems used primarily to secure 
reimbursements from the National Health Service. Each 
time a prescription is redeemed at a pharmacy, an electronic 
record is generated, including the customer’s CPR number, 
the type and amount of drug prescribed according to the 
Anatomical Therapeutic Chemical classification system, 
and the date of dispensing. The National Health Service 
gathers this information for administration of the drug reim-
bursement plan and then transfers this information to the 
DNHSPD.15 The DNHSPD contains data on all reimbursed 
prescriptions, including prescriptions written by physicians 
working in hospital clinics or private practices and redeemed 
at Danish pharmacies since 2004. However, drugs that are 
not reimbursed (eg, oral contraceptives or oseltamivir) are 
not captured in the database. Our expectation is that .60% 
of the women in our study sample redeemed a prescription 
during pregnancy,1 ie, .30,000 prescriptions during preg-
nancy annually. Table 2 illustrates the information available 
in the DNHSPD.
Data quality
Data quality depends on the validity of the exposures, the 
covariates, and the outcomes. The validity of information on 
drug exposure can be considered on two levels: “administra-
tive” level (the ability of the data source to correctly record 
redeemed prescriptions) and compliance level (the correspon-
dence between redeemed prescriptions and actual intake). 
Administrative-level information is expected to be highly 
valid and independent of the type of medication, as prescrip-
tion drugs in Denmark are only sold by certified pharmacies; 
information from each prescription is stored to allow financial 
reimbursement, and the information is reported to the central 
registry in a standardized way. In contrast, the validity of the 
compliance-level information depends on the type of medica-
tion, for example, high for long-acting insulin and low for 
antimigraine medication. A recent study found that 30% of 
women who redeemed a prescription for selective serotonin 
reuptake inhibitors (SSRIs) during pregnancy did not report 
SSRI use in a written questionnaire completed during the first 
trimester of pregnancy, and of the women who were coded 
as unexposed based on the DNHSPD, 26% did report use 
in the questionnaire.19 Exposure measured according to the 
four combinations of self-reported SSRI use and redeemed 
prescriptions changed the number of exposed pregnancies 
from 269 to 431 among 97,508 total pregnancies.19
The validity of the covariate data depends on the specific 
variables in question. For example, information on the sex 
of offspring is expected to be 100% valid. In contrast, infor-
mation on smoking during pregnancy, which is recorded 
by the sonographer at the time of the first-trimester screen-
ing and by the midwife at birth, may be subject to bias 
(eg, underreporting due to social norms). Thus, the use of 
smoking information mandates careful monitoring of poten-
tial changes during pregnancy.
The validity of the outcome will depend on the complete-
ness of the registration and the quality of the diagnoses. 
Table 1 list of central variables in the danish Fetal Medicine 
database
Maternal characteristics
CPR number
Age
Ethnicity
Weight
Smoking
Method of conception
Pregnancy information
Parity
Singleton/multiple pregnancies
Nuchal translucency thickness
Prenatally diagnosed malformations
 ICd-10 coded
 Anatomy coded (eg, major CNS malformation)
Results of invasive prenatal testing
Abbreviations: CNS, central nervous system; CPR, civil personal register number; 
ICd-10, International Classification of Diseases, tenth revision.
Table 2 Central variables in the danish National health Service 
Prescription database
Maternal characteristics
CPR number
Municipality and region of residence
Dispensing details
trade name
AtC code
ddd
date of dispensing
Abbreviations: AtC, Anatomical therapeutical Chemical; CPR, civil personal 
register number; DDD, defined daily dose.
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One core aim of the new linked data source is to decrease the 
risk of selection bias due to terminations because of malfor-
mations. We expect a dramatic increase in the detection rate 
of severe malformations associated with a high propensity 
for pregnancy termination, such as anencephaly.11 As well, 
the linked data source will allow more complete registra-
tion of malformations diagnosed at birth or even months or 
years after birth, for example, hypospadias or atrial septal 
defects.
Algorithms will be constructed to estimate the conse-
quences of potential errors in measuring the use of specific 
medications and prevalence of malformations based on 
validation studies. This will enable researchers to estimate 
the range of a specific teratogenic effect. For example, 
patients often purchase migraine medication to be prepared 
for future migraine attacks and, consequently, redeemed 
prescriptions will only lead to exposure in a certain pro-
portion of pregnancies. This proportion may be unknown, 
but the discrepancy could severely bias the estimates (in 
general, toward the null). We will provide estimates of the 
consequences of the expected range of misclassifications 
(eg, in the case of migraine medication, if the assumption 
is that between 20% and 50% of the redeemed prescrip-
tions are actually used, the algorithm will estimate the 
corresponding bias).
Strengths and weaknesses
The linked data hold an unequaled potential for comprehen-
sive evaluation of the safety of medication used in pregnancy. 
The database will have a sufficiently large sample size to 
provide important information on many types of existing 
medication and will be able to address safety concerns even 
on newly marketed medication owing to the regular update. 
Because of the unique information on prenatally diagnosed 
malformations, it will be able to detect potential associations 
between medication and, eg, anencephaly that are undetect-
able in data on live-born children only.
The main weakness is the potential misclassification of 
exposure and outcome variables inherent to register based 
research. This is specifically true for the paramount informa-
tion on medication exposure. For example, in the case of new 
medication, we expect no valid information on the potential 
noncompliance to prescriptions. This might limit the abil-
ity to detect teratogenic associations. The above-described 
algorithm will enable researchers to estimate the magnitude 
of the bias based on prior expectations of the misclassifica-
tions, but validation studies are much needed to test support 
expectations.
Accessing the data
The Department of Clinical Epidemiology at Aarhus 
University will maintain the new linked database for 
research purposes. The original data files for the Dan-
ish Fetal Medicine Database are kept by the Danish 
Regions’ Quality Assessment Unit, while the original 
data files for the DNHSPD are kept by the Department 
of Clinical Epidemiology at Aarhus University. The Dan-
ish Act on Processing of Personal Data20 permits public 
institutions, including universities, to retain individually 
identifiable health data for research purposes. Access 
will require permission from the Steering Group of the 
Danish Fetal Medicine Database. Furthermore, the use 
of any health data mandates project-specific permission 
from the Data Protection Agency (“Datatilsynet,” www. 
datatilsynet.dk). External researchers can apply for access 
to specific projects when the data have been validated. 
For medications for which there is no direct information 
on the validity of using reimbursements as proxy for intake, 
the expected range of correspondence needs to be stated in 
the protocol prior to the analyses. For instance, the protocols 
for proposed studies on migraine medication need to address 
the expected low correspondence. Similarly, prior estimates 
of the range of validity for data on specific malformations 
need to be explicitly stated in the protocol.
Conclusion
The new linked data source will provide a unique source of 
information on the teratogenic potential of medications used 
during pregnancy.
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